Kenneth C Frazier bought stock once, on Feb 4, 2026

Kenneth C. Frazier (born December 17, 1954) is an American business executive and attorney who serves as an independent director on the board of Eikon Therapeutics, Inc. (EIKN), where he recently engaged in insider trading as reported in Form 4 filings( A Philadelphia native, he earned a bachelor’s degree in Political Science from Pennsylvania State University and a J.D. from Harvard Law School, then practiced as a partner at Drinker Biddle & Reath before joining Merck & Co. in 1992(

At Merck, Frazier advanced through roles including general counsel, president of Global Human Health, and ultimately CEO and chairman from 2011 to 2021, becoming the first African American to lead a major pharmaceutical company; under his leadership, the company advanced innovations like KEYTRUDA and dozens of new medicines( Now retired from Merck, he is chairman of Health Assurance Initiatives at General Catalyst, advising on healthcare investments, and serves on boards including Eikon Therapeutics (since April 1, 2022), Paradigm, Transcarent, Weill Cornell Medicine, and Memorial Sloan Kettering Cancer Center( Frazier is renowned for advocacy in social justice as co-founder and co-chair of OneTen and has received awards like the Forbes Lifetime Achievement Award for Healthcare(

Written by Perplexity from public sources.